Abstract: AIM: To observe the effect of terlipressin in the management of patients with hepatorenal syndrome. METHODS: 60 patients were divided into two groups.In Group A, terlipressine was used and Group B was control group.The clinical manifestation, laboratory examination, turnover were observed during treatment. RESULTS: Compared with Group B, the effective power, the mean arterial pressure and the total urine output were increased significantly, the serum creatinine level was decreased remarkably. CONCLUSION: Terlipressin is safe and effective on hepatorenal syndrome with minute adverse reaction.

Key words: hepatorenal syndrome, tterlipressin, vasoactive agent, pharmacotherapy